Technologies in the News
Technologies in the News
-
Inside the Invention of the Stanford Router That Inspired Cisco
Bill Yeager’s multiprotocol router, invented on campus in 1980, was the basis for Cisco’s first product.
October 08, 2025
-
July 09, 2025
-
Illuminating the Immune System with Silicon Photonics
From Stanford OTL's Annual Report for Fiscal Year 2023-2024: "Bridging to Impact"
June 11, 2025
-
Tiny But Bright: High-Performance Lasers Go Chip Scale
From Stanford OTL's Annual Report for Fiscal Year 2023-2024: "Bridging to Impact"
June 11, 2025
-
Secret Sauce: A New Hydrogel for Vaccines, Surgical Recovery, Wildfires, and More
From Stanford OTL's Annual Report for Fiscal Year 2023-2024: "Bridging to Impact"
June 11, 2025
-
Two Steps Forward: New Integrin-Binding Molecule is a ‘Guided Missile’
From Stanford OTL's Annual Report for Fiscal Year 2023-2024: "Bridging to Impact"
June 11, 2025
-
Stanford Licensee Abeona Therapeutics receives U.S. FDA Approval for ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure.
April 29, 2025
-
New tool lets scientists observe genome dynamics in real time
A technique to see DNA as it moves in living cells could offer novel fundamental insights into biology.
April 25, 2025
-
Stanford Licensee Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for FSHD
Epic Bio is a biotechnology company focused on developing curative therapies.
April 03, 2025
-
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
Vera Therapeutics has announced an exclusive license agreement with Stanford University.
January 13, 2025
-
Stanford Licensee Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting
Synthekine Inc., which was founded on tech licensed from K. Christopher Garcia’s Stanford lab, today announced positive initial results from a first-in-human Phase 1 study.
December 09, 2024
-
BridgeBio's Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
Acoramidis is based on a Stanford technology licensed by Eidos Therapeutics, which BridgeBio acquired in 2021.
November 22, 2024
-
Stanford Licensee Valora Therapeutics Raises $30 Million Seed Financing from Top Investors to Transform Immunotherapy with a Novel Glyco-immune Checkpoint Platform
Valora, a biotech company pioneering a novel approach to immunotherapy, today announced the successful closing of its seed funding round.
November 20, 2024
-
Stanford Licensee Lightmatter Raises $400M Series D; Quadruples Valuation to $4.4B as Photonics Leader for Next-Gen AI Data Centers
Amid unprecedented demand for extreme-scale data centers, Lightmatter prepares for next phase of growth.
October 16, 2024
-
Metabolize, a startup founded on technology licensed from Stanford, Unveils Groundbreaking Weight Reduction Metabolite, with Breakthrough Findings Published in Nature
The newly published research highlights N-acetyltaurine's (NAT) potential for significant weight loss through appetite suppression.
September 10, 2024
-
Metabolize Licenses Two Proprietary Metabolites to Address Obesity from Stanford OTL
The licensing agreement is for two promising metabolites with the potential to significantly improve metabolic health and naturally address the obesity epidemic.
July 30, 2024
-
Magnus Medical Receives FDA Clearance for the SAINT Neuromodulation System for Non-Invasive, Individualized and Precise Treatment of Severe Depression
Magnus Medical Receives FDA Clearance for the SAINT Neuromodulation System for Non-Invasive, Individualized and Precise Treatment of Severe Depression
September 22, 2022
-
BridgeBio Pharma Announces Collaborations with Three Academic Research Institutions
Research collaborations initiated with MUSC Foundation for Research Development, SU and the U of Pittsburgh to identify and advance therapies for genetic diseases and cancers.
July 08, 2021
-
Graphite Bio Secures $150 Million Series B Financing to Advance Pipeline of Next-Generation Gene Editing Therapies
Total of $195 million raised to date. | The financing, led by RA Capital Management and Rock Springs Capital, included participation by other prominent new and existing investors.
March 15, 2021
-
DiCE Gets Its 'Library' Card Ready As It Speeds Development Of DNA Database-derived Molecules with More Investor Cash
The DiCE Molecules CEO is plotting a clinical trial launch for the biotech’s lead small molecule for psoriasis and wants to double the staff in the next year and a half.
January 08, 2021
